Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. on July 2, 2021. The filing reports the entry into a material definitive agreement to establish an "at-the-market" equity offering program. Note: The request metadata referenced "Avalo Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the potential capital raise:
- Maximum Offering Size: Up to $50,000,000 in aggregate offering price.
- Commission Rate: 3.0% of gross proceeds paid to agents (Cantor Fitzgerald & Co. and RBC Capital Markets, LLC).
Material Changes
The material change reported is the execution of a Controlled Equity Offering Sales Agreement on July 2, 2021. This agreement authorizes the company to sell shares of its common stock through the designated agents based on the company's instructions. No prior comparable period data is provided in this specific filing.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The company has established a mechanism to raise capital as needed, subject to market conditions and the company's discretion to suspend or terminate the offering.
Risks and Contingencies: The filing includes Supplemental Risk Factors (Exhibit 99.1) related to the offering. The company has agreed to provide customary indemnification and contribution rights to the agents. The sale of shares is subject to the terms of the agreement and applicable securities laws.
Investor Verification Checklist
- Verify the exact number of shares sold and gross proceeds received under this agreement in subsequent filings (e.g., Form 10-Q or 10-K).
- Review the Supplemental Risk Factors in Exhibit 99.1 for specific risks associated with the equity offering.
- Confirm the current share count and potential dilution impact based on the $50 million cap.
- Check for any suspensions or terminations of the offering program in future 8-K filings.